Acute Myeloid Leukemia Aml Pipeline Insight

DelveInsight’s, “Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Acute Myeloid Leukemia (AML) Understanding

Acute Myeloid Leukemia (AML): Overview

Acute Myeloid Leukemia (AML) (AML) starts in the bone marrow (the soft inner part of certain bones, where new blood cells are made), but most often it quickly moves into the blood, as well. It can sometimes spread to other parts of the body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord), and testicles. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells. Acute Myeloid Leukemia (AML) (AML) has many other names, including acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia.


"Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Myeloid Leukemia (AML) pipeline landscape is provided which includes the disease overview and Acute Myeloid Leukemia (AML) treatment guidelines. The assessment part of the report embraces, in depth Acute Myeloid Leukemia (AML) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Myeloid Leukemia (AML) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Myeloid Leukemia (AML) R&D. The therapies under development are focused on novel approaches to treat/improve Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia (AML) Emerging Drugs Chapters

This segment of the Acute Myeloid Leukemia (AML) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Acute Myeloid Leukemia (AML) Emerging Drugs


BST-236: BioSight

Aspacytarabine (BST-236) is a novel proprietary anti-metabolite. It is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine, enabling delivery of high cytarabine doses to leukemia patients with lower systemic exposure to the free drug. The drug is currently in phase 2 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).


Uproleselan: GlycoMimetics

GlycoMimetics is developing uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with Acute Myeloid Leukemia (AML) (AML) and potentially other hematologic cancers. The drug is currently in phase 3 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).


Sabatolimab: Novartis

Sabatolimab is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody being developed by Novartis. The drug is currently in phase 2 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).


Pevonedistat: Takeda

Pevonedistat is a first in class NEDD8-activating enzyme (NAE) inhibitor. In pre-clinical studies, the inhibition of NAE by pevonedistat blocked the modification of select proteins, which resulted in disruption of cell cycle progression and cell survival, leading to cancer cell death. The drug is currently in phase 3 of clinical trials for the treatment of Acute Myeloid Leukemia (AML).

Further product details are provided in the report……..

Acute Myeloid Leukemia (AML): Therapeutic Assessment

This segment of the report provides insights about the different Acute Myeloid Leukemia (AML) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Acute Myeloid Leukemia (AML)

There are approx. 100+ key companies which are developing the therapies for Acute Myeloid Leukemia (AML). The companies which have their Acute Myeloid Leukemia (AML) drug candidates in the most advanced stage, i.e. phase III include, GlycoMimetics.

Phases

DelveInsight’s report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Acute Myeloid Leukemia (AML) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Myeloid Leukemia (AML): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Myeloid Leukemia (AML) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Myeloid Leukemia (AML) drugs.

Acute Myeloid Leukemia (AML) Report Insights

  • Acute Myeloid Leukemia (AML) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute Myeloid Leukemia (AML) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute Myeloid Leukemia (AML) drugs?
  • How many Acute Myeloid Leukemia (AML) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Myeloid Leukemia (AML)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Myeloid Leukemia (AML) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Myeloid Leukemia (AML) and their status?
  • What are the key designations that have been granted to the emerging drugs?


Introduction

Executive Summary

Acute Myeloid Leukemia (AML): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Acute Myeloid Leukemia (AML) – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Acute Myeloid Leukemia (AML) companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Acute Myeloid Leukemia (AML) Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Uproleselan: GlycoMimetics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

BST-236: BioSight

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Acute Myeloid Leukemia (AML) Key Companies

Acute Myeloid Leukemia (AML) Key Products

Acute Myeloid Leukemia (AML)- Unmet Needs

Acute Myeloid Leukemia (AML)- Market Drivers and Barriers

Acute Myeloid Leukemia (AML)- Future Perspectives and Conclusion

Acute Myeloid Leukemia (AML) Analyst Views

Acute Myeloid Leukemia (AML) Key Companies

Appendix

List of Table

Table 1: Total Products for Acute Myeloid Leukemia (AML)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Acute Myeloid Leukemia (AML)

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products      

• BioSight

• GlycoMimetics

• Novartis

• Takeda

• Menarini Group

• ImmunoGen

• Kartos Therapeutics

• Plexxikon

• Shijiazhuang Yiling Pharmaceutical

• Oscotec

• Ryvu Therapeutics

• Aptose Biosciences

• Innovent Biologics

• JW Pharmaceutical

• Hanmi Pharmaceutical

• GEMoaB Monoclonals

• ALX Oncology

• I-Mab Biopharma

• DCPrime BV

• Amgen

• Synimmune GmbH

• BioTheryX

• Celyad Oncology

• Cleave Therapeutics

• Astex Pharmaceuticals

• Amphivena Therapeutics

  • Tags:
  • Acute Myeloid Leukemia (AML) Pipeli...
  • Acute Myeloid Leukemia (AML) clini...
  • Acute Myeloid Leukemia (AML) compa...
  • Acute Myeloid Leukemia (AML) drugs
  • Acute Myeloid Leukemia (AML) thera...
  • Acute Myeloid Leukemia (AML) treat...
  • Acute Myeloid Leukemia (AML) pipel...
  • Acute Myeloid Leukemia (AML) pipel...

Forward to Friend

Need A Quote